接受 CAR-T 治疗的血液系统恶性肿瘤患者的生活质量与症状负担：一项横断面研究

Few studies have thoroughly evaluated the symptom burden and quality of life (QOL) among patients diagnosed with hematologic malignancies who underwent chimeric antigen receptor T-cell (CAR-T) therapy. In total, 97 eligible patients completed the Functional Assessment of Cancer Therapy generic scale (FACT-G) at week 4 after CAR-T cell infusion.

We used the Common Terminology Criteria Adverse Events (CTCAE) to measure symptom burden of CAR-T patients during the same period.

We studied factors associated with QOL using liner regression analysis. During the period of hospitalization after CAR-T treatment, the prevalence of self-reported symptoms among CAR-T patients was highest for fatigue (89. 7%), followed by sleep disorders (79. 4%) and decreased appetite (66. 0%). And the mean score of FACT-G was 69. 06 (SD = 13. 88). Liner regression analysis showed that decreased appetite ( = -0. 30, 95% CI = -7. 48 to -1. 83, P = 0. 002), fatigue ( = -0. 28, 95% CI = -7. 23- -1. 69, P = 0. 002), nausea ( = -0.

26, 95% CI = -10. 50 to -2. 16, P = 0. 003) and a history of hematopoietic stem cell transplantation (HSCT) ( = -0. 21, 95% CI = -13. 38- -1. 56, P = 0. 014) were associated with poorer quality of life. The symptom burden experienced by patients undergoing CAR-T treatment is substantial during their hospitalization, and it is closely associated with a diminished quality of life. It is imperative for clinical medical staff to be attentive to the symptom burden of CAR-T patients and to enhance the effectiveness of symptom management interventions.